Compare Merck & Co., Inc. (MRK) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs NEOS S&P 500 High Income ETF — how do they compare? Merck & Co., Inc. trades at $142.33 (market cap $351.28B), while NEOS S&P 500 High Income ETF trades at $54.04 (market cap $12.50B). The key difference: Merck & Co., Inc. is far larger — about 28.1× NEOS S&P 500 High Income ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while NEOS S&P 500 High Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and NEOS S&P 500 High Income ETF for 57 Days on average.
| MRK | SPYI | |
|---|---|---|
Market Cap | $351.28B | $12.50B |
Volume | 7,969,665 | 3,058,962 |
Sector | Health | Income / Options Overlay |
52-Week High | $156.43 | $54.42 |
52-Week Low | $82.49 | $47.98 |
Typical Hold Time | 98 Days | 57 Days |
Enterprise Value | $398.04B | — |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% today, with a bearish technical signal but strong fundamental performance. The company reported revenue of $65.01B in 2025 with a net income margin of 28.07%, and recent quarterly EPS have consistently beaten expectations. Merck is actively expanding its pipeline through acquisitions, such as the pending $6.7B purchase of Terns Pharmaceuticals announced in April 2026.
The outlook is supported by solid profitability and analyst optimism, with a consensus price target of $158.78 implying upside. Key risks include integration challenges from acquisitions and competitive pressures in the oncology sector. Cash flow trends show variability, with a projected net cash outflow of $1.2B in 2026 due to significant investing activities.
SPYI trades at $54.01, down 0.13% with a bullish technical outlook from moving averages but neutral oscillators. The ETF maintains consistent monthly dividend distributions around $0.53-$0.54, though recent analysis highlights concerns about principal erosion from covered call strategies. Media coverage focuses heavily on retirement income strategies and the trade-offs between high yields and capital preservation.
The outlook remains cautious as SPYI faces scrutiny over whether its high income distributions come at the expense of long-term capital growth. While technical indicators suggest near-term strength, fundamental concerns about the sustainability of covered call returns and sequence risk for retirees present significant headwinds for investors seeking both income and principal protection.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
